Acquired in-process research and development accounting under U.S. GAAP works like this: when you buy a company with unfinished R&D projects, you record each qualifying project at its acquisition-date fair value as an indefinite-lived intangible asset, test it for impairment at least annually while development continues, and then either reclassify it as a finite-lived asset and amortize it once the project completes, or write it off if the project is abandoned. The treatment is deliberately different from how you account for your own internal R&D, and the mechanics turn on whether the deal is a business combination or an asset acquisition.
What Counts as Acquired IPR&D
IPR&D covers projects that are still actively under development when the deal closes. A drug candidate in clinical trials, a next-generation chip design still in the lab, an unreleased software product — the shared feature is that the technical work isn’t done and the outcome isn’t certain.
To be recognized separately from goodwill in a business combination, an IPR&D project has to qualify as an identifiable intangible asset under ASC 805. That requires meeting at least one of two criteria: the asset is separable, meaning it could be sold, licensed, or transferred independently of the acquired company, or it arises from contractual or legal rights such as a patent application or licensing agreement.1Deloitte. Roadmap Business Combinations – 4.10 Intangible Assets A project that fails both tests stays buried in goodwill.
The acquisition context is what enables separate recognition. The negotiated purchase price reflects the market’s view of each developing project’s potential, providing an arm’s-length measurement basis that internal R&D lacks.
Measuring Fair Value at the Acquisition Date
During purchase price allocation, every identifiable asset and assumed liability gets measured at fair value as of the acquisition date. IPR&D is no exception. You have to carve out the value tied to each developing project rather than sweep it into goodwill.
Because IPR&D rarely trades in active markets, valuation specialists use the income approach — the present value of projected future cash flows the project is expected to generate.2Accounting Today. AICPA Issues Accounting and Valuation Guide for IPR&D The most common technique is the multi-period excess earnings method, which projects cash flows over the product’s expected commercial life assuming successful completion, subtracts charges for contributory assets like working capital and existing technology, and discounts the residual back to present value.
Two inputs make the number especially sensitive. The first is the probability of technical and commercial success, which adjusts projected cash flows downward for the risk that the project never reaches the market. A late-stage pharmaceutical compound with Phase III data might carry an 80% probability, while an early-stage platform technology could sit well below 30%. The second is the discount rate. Unproven projects carry more risk than established revenue streams, so the rate applied to IPR&D cash flows is significantly higher than the acquirer’s overall cost of capital. Small shifts in either input move the final value meaningfully, which is why independent third-party valuation experts are almost always engaged.
The resulting fair value is capitalized on the acquirer’s balance sheet. That amount is the starting point for everything that follows.
Measurement Period Adjustments
Purchase price allocations often rely on provisional estimates, and IPR&D is one of the items most likely to need refinement. ASC 805 gives the acquirer a measurement period to update those provisional amounts as new information about facts and circumstances existing at the acquisition date comes to light. The period ends when the acquirer receives the information it was looking for, and in any event cannot extend beyond one year from the acquisition date.3Deloitte. Roadmap Business Combinations – 6.1 Measurement Period
If you find during that window that a project was further along or less advanced than first estimated, you adjust the provisional fair value with a corresponding adjustment to goodwill. The revised accounting is applied as if it had been in place from the acquisition date, so any catch-up effects on amortization or other income items hit the current period.
Holding the Asset While Development Continues
While the R&D project remains in progress, the asset carries an indefinite useful life and is not amortized. Instead, it must be tested for impairment at least once a year under ASC 350.4Deloitte. 4.4 Intangible Assets Not Subject to Amortization More frequent testing is required when triggering events occur — a failed clinical trial, a change in the competitive environment, or a significant cut to project funding, for example.
The test can start with a qualitative “Step 0” assessment: is it more likely than not (greater than 50% probability) that the asset is impaired? If not, no further testing is needed. If the qualitative screen points toward impairment, you calculate current fair value and, when carrying value exceeds it, recognize the difference as an impairment loss on the income statement.
When the Project Completes or Fails
Every acquired IPR&D asset eventually exits the indefinite-lived bucket, one of two ways.
Successful Completion
When the associated R&D efforts finish, the asset is reclassified from indefinite-lived to finite-lived. Completion looks different by industry: regulatory approval to market a drug, commercial readiness for a technology product.5U.S. Securities and Exchange Commission. SEC EDGAR Filing – Intangible Assets Disclosure Reclassification triggers a required impairment test at that date, before amortization begins.
Once reclassified, the asset is amortized over its estimated useful life, generally on a straight-line basis, with amortization expense flowing through the income statement each period. Management should reassess the remaining useful life periodically and adjust the amortization period prospectively when circumstances change.
Failure or Abandonment
If the project fails or management stops pursuing it, the carrying value is written down and the loss recorded as impairment. One nuance: AICPA guidance cautions that an asset tied to an abandoned project may still serve a “defensive” purpose, protecting or enhancing other assets. A company might halt active development of a technology but keep the underlying patent to block competitors, in which case a full write-down to zero may not be appropriate.
Business Combination vs. Asset Acquisition
Everything above assumes the deal is a business combination — the buyer obtains control of an actual business. When the transaction is an asset acquisition instead (a purchase of assets that don’t constitute a business), the accounting for IPR&D flips.
In an asset acquisition, IPR&D with no alternative future use is expensed immediately under ASC 730, the same treatment as internal R&D. Only IPR&D that has an alternative future use, meaning it could be used in other projects if the current one fails, can be capitalized.6Deloitte. Roadmap Business Combinations – C.3 Allocating the Cost in an Asset Acquisition
The reporting effect is substantial. Two identical projects can be accounted for very differently depending on deal structure. Buy a single drug candidate through an asset purchase and the entire cost hits the income statement on day one. Buy the same drug candidate by acquiring the business that developed it and the cost sits on the balance sheet as an indefinite-lived intangible. Confirming which side of that line a transaction falls on is one of the first questions to answer in purchase accounting.
How This Differs From Internal R&D
The contrast with internally generated R&D is one of the more striking asymmetries in U.S. GAAP. Under ASC 730, R&D costs a company incurs on its own projects must be expensed as incurred, no matter how promising the pipeline looks.7FASB. Research and Development (Topic 730) – Proposed ASU
The rationale is measurement reliability. Internal programs have no arm’s-length transaction to anchor a value; the link between lab spending and future revenue is too speculative for balance sheet recognition. Acquired IPR&D sidesteps the problem because the negotiated acquisition price supplies a market-based measurement.
The practical consequence: two companies with comparable R&D pipelines can look very different on paper depending on how those pipelines were built. The acquirer carries capitalized IPR&D assets and reports lower R&D expense. The organic developer carries no such asset and reports higher cumulative R&D expense. Anyone comparing the two needs to adjust for that gap.
IFRS and Tax Wrinkles
IFRS reporters follow a broadly similar approach for acquired IPR&D. IFRS 3 requires separate recognition from goodwill when the separability or contractual-legal criterion is met, the same framework as U.S. GAAP.8IFRS Foundation. IFRS 3 Business Combinations The larger difference between the two frameworks is on the internal side: IAS 38 splits internal projects into a research phase (always expensed) and a development phase (capitalized when specific conditions are met, including technical feasibility and probable future economic benefits). IFRS reporters may capitalize late-stage internal development costs that U.S. GAAP reporters have to expense.
On the tax side, GAAP treatment of acquired IPR&D and its tax treatment have long diverged. Starting in 2022, Section 174 required companies to capitalize and amortize R&D expenditures over five years for domestic research and fifteen years for foreign research. The One Big Beautiful Bill Act reversed that for domestic research: under new Section 174A, domestic research and experimental expenditures are immediately deductible for tax years beginning after December 31, 2024. Foreign research expenditures still have to be capitalized and amortized over fifteen years. For acquired IPR&D, the GAAP capitalize-and-hold treatment and the tax treatment routinely produce timing differences that generate deferred tax assets or liabilities, so tax and accounting teams need to work the purchase accounting together.